Mandy Starbuck
Nurse Practitioner · Greenville, NCNPI 1245564160
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,988 of the $13,083 with a category attached, or 68.7%. 37 manufacturers reported payments, led by Abbott at 45.0% of the total. Reporting peaked in 2021 at $5,346 and has fallen 72.7% since, to $1,461 in 2025. Among nurse practitioner clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- E.r. Squibb & Sons, L.L.C.$1K
- Novartis$736
- AstraZeneca$652
- Amgen$605
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$503
- plus $4K from 31 others
What the payments were for
- Consulting fees$3,12024%
- Travel & lodging$9057%
- Food & beverage$8,98869%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 88 | $5,890 |
| E.r. Squibb & Sons, L.L.C. | 110 | $1,069 |
| Novartis | 66 | $736 |
| AstraZeneca | 24 | $652 |
| Amgen | 50 | $605 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $503 |
| Boston Scientific | 16 | $388 |
| Pfizer | 32 | $376 |
| Novo Nordisk | 15 | $346 |
| Sanofi-aventis U.S. LLC | 18 | $297 |
| Merck | 18 | $255 |
| Boehringer Ingelheim | 14 | $236 |
| Cvrx, Inc. | 6 | $236 |
| Recor Medical Inc | 1 | $184 |
| Amarin Pharma, Inc. | 10 | $162 |
| Johnson & Johnson | 11 | $153 |
| Abiomed | 1 | $147 |
| Medtronic | 4 | $146 |
| Kowa Pharmaceuticals America, Inc. | 5 | $69 |
| Scpharmaceuticals Inc. | 3 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $67 |
| Lexicon Pharmaceuticals, Inc. | 4 | $64 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Vifor Pharma, Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $42 |
| Bayer | 2 | $36 |
| Irhythm Technologies, Inc. | 1 | $30 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Bioxcel Therapeutics, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$2,668
- CARDIOMEMS$1,144
- CAMZYOS$240
- Paradise Ultrasound Renal Denervation System$184
- FARXIGA$125
How this compares
$13,083 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 812 | $613,865 |
| FarxigaDapagliflozin Propanediol | 550 | $353,507 |
| EliquisApixaban | 374 | $267,370 |
| Repatha SureclickEvolocumab | 168 | $117,827 |
| JardianceEmpagliflozin | 95 | $67,601 |
| BrilintaTicagrelor | 82 | $42,237 |
| XareltoRivaroxaban | 56 | $39,332 |
| VerquvoVericiguat | 36 | $23,158 |
| DapagliflozinDapagliflozin Propanediol | 35 | $17,726 |
| Ranolazine ErRanolazine | 256 | $15,493 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 42 | $13,192 |
| Repatha PushtronexEvolocumab | 11 | $6,397 |
| Bumetanide | 101 | $5,034 |
| VascepaIcosapent Ethyl | 11 | $4,373 |
| Metoprolol Succinate | 513 | $3,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $736 | $613,865812 claims |
| AstraZenecaFarxiga, Brilinta | $652 | $395,744632 claims |
| PfizerEliquis | $376 | $267,370374 claims |
| Boehringer IngelheimJardiance | $236 | $67,60195 claims |
| Johnson & JohnsonXarelto | $153 | $39,33256 claims |
| MerckVerquvo | $255 | $23,15836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Greenville
- Sandrivette JohnsonRaleigh$573K
- Ayeshia WrightMocksville$145K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
- Deborah MayerChapel Hill$55K
- Amber SeilerGreensboro$55K
- Stephanie PascaleRaleigh$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.